Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
作者机构：Gastroenterology and Hepatology Division of the Second Propedeutic Department of Internal MedicineHippokration General HospitalMedical SchoolAristotle University of ThessalonikiThessaloniki 54642Greece
出 版 物：《World Journal of Transplantation》 (世界移植杂志)
年 卷 期：2022年第12卷第9期
页 面：281-287页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Non-alcoholic fatty liver disease Steatohepatitis Hepatic steatosis Liver transplantation Cirrhosis Metabolic syndrome
摘 要：Non-alcoholic fatty liver disease(NAFLD)is one of the leading causes of chronic liver disease,cirrhosis,and hepatocellular carcinoma worldwide,with an estimated prevalence of 25%.Post-liver transplantation(LT)recurrent or de novo hepatic steatosis is a common complication in recipients,irrespective of transplantation *** factors for graft steatosis mainly include obesity,immunosuppression,donor steatosis,and genetic *** transplant recipients are at high risk of developing insulin resistance,new-onset diabetes,and posttransplantation metabolic syndrome that is highly associated with immunosuppressive ***-LT NAFLD is often underdiagnosed due to the poor sensitivity of most routine imaging *** gold standard for the diagnosis of hepatic steatosis is liver biopsy,which is,however,limited to more complex cases due to its invasive *** is no approved pharmacotherapy in *** modification remains the cornerstone in NAFLD *** treatment strategies in post-LT NAFLD include lifestyle modifications,pharmacotherapy,bariatric surgery,and tailored ***,these approaches originate from recommendations in the general population,as there is scarce data regarding the safety and efficacy of current management strategies for NAFLD in liver transplant *** prospective studies are required to achieve tailored treatment for these patients.
维普期刊数据库